Oligomerix

About

Oligomerix develops target identification and validation technologies enhancing the drug discovery process for neurodegenerative diseases.

Bronx,New York,United States
1 - 10

Highlights

Details

Last Funding Type: Grant
Last Funding Money Raised: $3.35M
Industries: Biotechnology,Ediscovery,Medical
Founded date: Jan 1, 2006
Number Of Employee: 1 - 10
Operating Status: Active
Legal Name: Oligomerix, Inc.

Oligomerix is a biopharmaceutical company founded in 2006 by co-founders Eliot J. Davidowitz and James Moe. The Company is exploiting its novel research that allows rapid generation of stable amyloid oligomers as targets for drug discovery. These systems will enable target identification and validation, and drug discovery for Alzheimer's and other neurodegenerative diseases.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

8

$17.62M

Oligomerix has raised a total of $17.62M in funding over 2 rounds. Their latest funding was raised on Aug 10, 2022 from a Grant round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Aug 10, 2022	Grant	$2.49M	1	National Institute on Aging	—	Detail
Aug 9, 2022	Grant	$3.35M	1	National Institutes of Health	—	Detail
Jun 2, 2022	Series B	$2.70M	—	—	—	Detail
Oct 10, 2019	Grant	$2.18M	1	Small Business Innovation Research	—	Detail
Apr 15, 2015	Series Unknown	$400K	—	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

3

6

Oligomerix is funded by 6 investors. National Institute on Aging and National Institutes of Health are the most recent investors.

Investor Name	Lead Investor	Funding Round
National Institute on Aging	Yes	Grant
National Institutes of Health	Yes	Grant
Small Business Innovation Research	Yes	Grant
Wheatley MedTech Partners	—	Series A
Durand Venture Associates	—	Series A
Wheatley Partners	—	Series A